Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Depression is one of the most common forms of mental illness, affecting more than 350 million people worldwide. It is ranked by the World Health Organization as the leading cause of disability globally. Treatment usually involves either medication, some form of  psychotherapy or a combination of both. Yet many patients fail to get better and suffer recurring bouts of illness. MBCT was developed to help such people by teaching them skills to recognize and respond constructively to thoughts and feelings associated with relapse, aiming to prevent a downward spiral into depression. In the first large study to compare MBCT and anti-depressants, researchers found little difference in outcomes. In terms of cost, mindfulness training — often viewed as more costly because it requires more time with a trained therapist — was not significantly more pricey, particularly when given in group sessions, the study found. Richard Byng, a professor at Britain’s Plymouth University Peninsula Schools of Medicine and Dentistry, said that, while current standard treatment for chronic depression is to keep taking anti-depressants, many people don’t want to take them for long periods and others want to avoid side-effects. In this study, 424 adults with recurrent major depression who were on maintenance anti-depressant drugs were randomly assigned either to come off their anti-depressants slowly and receive MBCT or to stay on their medication. While 212 patients continued taking their anti-depressants, the other 212 attended eight group mindfulness therapy sessions and were given daily home practice as well as an option to have four follow-up sessions over a 12-month period. Study results published in The Lancet medical journal showed that after two years, relapse rates were similar in both groups — at 44 percent in the therapy group versus 47 percent in the anti-depressant drug group. “Whilst this study doesn’t show that mindfulness-based cognitive therapy works any better than maintenance anti-depressant medication in reducing the rate of relapse ... these results suggest a new choice for the millions of people with recurrent depression on repeat prescriptions,” said Willem Kuyken of Oxford University, who worked with Byng on the research. Claim: Mindfulness therapy as good as medication for chronic depression - study.

Output: Mindfulness-based cognitive therapy (MBCT) may be just as effective as anti-depressants in helping prevent people with chronic depression from relapsing, scientists said on Tuesday.


Input: Consider Input: Paragraph: The zoo said Tuesday that 9-year-old Jiao Qing was examined last week by experts at the city’s Leibniz Institute for Zoo and Wildlife Research after the discrepancy was picked up on an ultrasound. The 110-kilogram (243-pound) bear underwent the scan while under anesthesia. Doctors confirmed one kidney is smaller. The panda’s urine will be tested to determine whether the smaller kidney is functioning properly. Even if not, animals can live healthy lives with only one kidney. Jiao Qing is the father of twin cubs born Aug. 31. They are doing well. Claim: Grin and bear it: Berlin panda gets CT scan for kidney exam.

Output: A Berlin zoo says a giant panda whose twin cubs have captured international attention has undergone a CT scan after veterinarians discovered one of his kidneys was smaller than the other.


Input: Consider Input: Paragraph: The French drugmaker, whose pipeline has disappointed investors in recent years, poached new chief executive Paul Hudson from Swiss pharma group Novartis in September to revitalize the company. Its move to ditch diabetes research - announced alongside cost savings targets - marks a major turning point for a firm whose products dominated the insulin market for nearly two decades, before it was hit by patent losses and a drop in sales. “We recognize it is getting more difficult to get breakthrough innovation and that we have to be efficient and move our resources to areas of opportunity, as tough a choice as that is,” Hudson told reporters. The firm is bulking up elsewhere, as in the lucrative field of cancer drugs. It announced a deal to buy U.S. biotechnology firm Synthorx for about $2.5 billion earlier on Monday. Sanofi, which is due to further detail strategic plans to investors on Tuesday in Cambridge, Massachusetts, said it was targeting new cost savings of 2 billion euros ($2.20 billion) by 2022, by tightening spending and shaking up its supply chain. It also aims for a core operating margin of 30% by then, up from 25.8% last year. The group emphasized the potential for its eczema treatment Dupixent, recently approved in other therapeutic areas such as asthma, with an aim to expand sales to more than 10 billion euros. Revenue for the drug, developed with U.S. partner Regeneron Pharmaceuticals Inc, was up 268% in 2018, reaching 788 million euros. Sanofi, currently organized around five global business units, said it would rejig these around three pillars: specialty care, which includes oncology and rare diseases, as well as vaccines and general medicines. Its consumer healthcare unit - known for over-the-counter products such as paracetamol Doliprane, erectile dysfunction drug Cialis and influenza treatment Tamiflu - will be considered as a standalone business, Sanofi said. It would have its own operational dynamic, the firm added, though it did not clarify what this meant in the longer term. Sources told Reuters last month that Sanofi was considering a joint venture or an outright sale among options for the division. “Our objective for the consumer healthcare business is to unlock value and entrepreneurial energy by growing faster than the market over mid-term,” Hudson said. Claim: Accutane Linked Heart, Liver Woes


Output: Sanofi SA said on Monday it would end its research efforts in diabetes and cardiovascular diseases as part of a revamp that will narrow the number of its business units in the hope of bolstering growth and profit.